Clinical trial NCT04565847: The Effects of Salbutamol on Mannitol Induced Cough Responses in Healthy Controls
Official title: The Effects of Salbutamol on Mannitol Induced Cough Responses in Healthy Controls
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Cough
Lead sponsor: McMaster University
Sponsor class: OTHER
First posted: 2020-09-25
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: albutamol or placebo will be delivered following a mannitol cough challenge in a randomized, double-blind crossover design.
Primary purpose: OTHER

Brief summary: The study aim is to investigate if changes in osmolarity using mannitol challenge can evoke coughing healthy controls with no evidence of bronchoconstriction (PC20\>16mg/ml or mannitol PD15 \> 635 mg, or \< 10% incremental fall in FEV1 between consecutive mannitol doses) and if salbutamol can affect this. This is a double-blind, placebo-controlled analysis in healthy controls assessing the effects of salbutamol on mannitol induced cough.

Detailed description: The study will have a maximum of 4 visits separated by at least 24 hours. The first 2 visits will determine eligibility. All eligible subjects will be invited back for a third and a fourth visit.

Screening Period (Visits 1 and 2) - For All Subjects Eligible subjects will be identified during the initial screening procedures with measures of spirometry, hyperresponsiveness to methacholine, complete history, physical examination, allergen skin test, and mannitol cough challenge. The screening procedures will be conducted over 2 separate visits.

Effects of Salbutamol (Visit 3 and 4) - For Healthy Control Subjects, Twenty subjects with no evidence of asthma will return for visit 3 and 4. These visits must be at least 24h apart and no longer than 7 days. Health controls will first receive salbutamol 2.5mg or saline placebo via a nebuliser and 15 mins later the forced expiratory volume at one second (FEV1) measured. Subjects will then undergo a mannitol cough challenge exactly like the previous mannitol cough challenges. These data will be used for determining the effects of salbutamol on mannitol-induced cough.

Visit Windows Each visit must be separated by a minimum of 24 hours, and a maximum of 7 days. Study visits can be performed in the morning or afternoon, however for each subject the timing should be consistent with Visits 2 at the same time of day ± 2 hours

Eligibility criteria: Inclusion Criteria:

1. Able to understand and give written informed consent.
2. Male and female volunteers 18 through 65 years of age.
3. No airway hyperresponsiveness as determined by methacholine PC20\>16mg/ml or mannitol PD15 \> 635 mg, or \< 10% incremental fall in FEV1 between consecutive mannitol doses.
4. Fall in FEV1 of ≤ 5% after any mannitol dose during mannitol challenge compared to baseline FEV1 at 0 mg at screening mannitol challenge (Visit 2).
5. Baseline FEV1≥ 80% of the predicted value.
6. Demonstrate cough response to inhaled mannitol.

Exclusion Criteria:

1. Current or former smoker with \>10-pack-year history
2. Current or previous history of other significant respiratory disease
3. Significant systemic disease, including history of current malignancy or autoimmune disease
4. Pregnancy or breastfeeding.
5. Use of corticosteroids within 28 days prior to the first study visit.
6. Use of nonsteroidal anti-inflammatory drugs (NSAIDs) within 48 hours of study visits or aspirin with 7 days of study visits
7. Use of antihistamines including those in cold and allergy medications within 72 hours of study visits
8. Use of caffeine-containing products within 4 hours of study visits
9. Use of ACE inhibitors
10. Any centrally acting medication which in the view of the investigator could alter the sensitivity of the cough reflex including but not restricted to tricyclic anti-depressants, pregabalin, gabapentin, codeine, tramadol, or any other opioid.
11. Unwillingness or inability to comply with the study protocol for any other reason

Primary outcomes:
measure: Primary Outcome - Emax
timeFrame: Through study completion, an average of 1 year
Secondary outcomes:
measure: Cough dose response curves
timeFrame: Through study completion, an average of 1 year
measure: ED50
timeFrame: Through study completion, an average of 1 year
measure: C2
timeFrame: Through study completion, an average of 1 year
measure: C5
timeFrame: Through study completion, an average of 1 year
measure: Cumulative number of coughs
timeFrame: Through study completion, an average of 1 year
Other outcomes:
Locations:
city: Hamilton
country: Canada
facility: McMaster Cardio-Respiratory Research Lab
state: Ontario
city: Hamilton
country: Canada
facility: McMaster University
state: Ontario
Study officials:
affiliation: McMaster University Hospital
name: Gail Gauvreau, PhD
role: PRINCIPAL_INVESTIGATOR
References: